GGI Legacy Site
We have a new look. Please see our new home page.
GGI RapidNews R&D Product Development eZine: Volume
2, Issue 4 - May 4, 2001
GGI RapidNews is published monthly
Metrics Survey: Free downloadable copies of the 2000 R&D
Metrics Survey Description and/or Survey Questionnaire are available
in our Market Research Reading Room at http://www.goldensegroupinc.com/readmarket.shtml.
You will also find free downloadable files for GGI's 1998 Product
Development Metrics Survey. The 1998 and some 2000 Metrics Survey
results are now available for purchase at http://www.goldensegroupinc.com/cgi/catalog.cgi?display_p355.
Each month GGI
shares selected R&D survey results with RapidNews readers.
One primary purpose of the 2000 Survey was to explore the
degree of linkage between R&D strategy and overall corporate
business strategy. This month's results are listed below for
your interest and consideration:
- The 86% of
companies that have stated, or say they can derive a set
of company-wide Corporate Metrics, plus the 75% of companies
that have stated, or say they can derive a set of R&D
Metrics were asked about the linkage between the two respective
sets of metrics portfolios. For those companies which can
establish a linkage, implying that linked metrics portfolios
mean linked strategies, 18% had no linkage. i.e., there
were no metrics in common. 67% had between 1 and 5 metrics
in common between their portfolios. 11% had between 6 and
9 metrics in common between their portfolios. 4% had 10
or more metrics in common between their portfolios.
- By dividing
the metrics common to the R&D and Corporate Metrics
portfolios by the total number of metrics in the Corporate
Metrics portfolio, it is possible to derive a "new-to-the-world
metric." The new metric is "% R&D Linkage
To Corporate Strategy." GGI calculated this metric
using both the mean (14%) and the median (17%). The median
is perhaps the more reliable statistical indicator for this
particular survey question. In either case, it appears that
R&D is adequately represented in the company-wide set
of Corporate Metrics.
Our next R&D
Metrics Survey will be conducted early in 2002. If you would
like to participate, please send me a reply e-mail
to get on our mailing list.
The 2001 International Forum on DFMA: Boothroyd-Dewhurst's
16th annual conference will be held this June 4-5 in Newport,
RI. Brad Goldense will present a paper based on GGI's 2000
R&D Metrics Survey entitled "Measuring R&D Portfolio
Success: Best Practices." GGI's survey explored portfolio
selection, management, and review processes; and the related
measures that leading companies are using to evaluate their
R&D portfolios. The survey queried product success/failure
rates and many other attributes of portfolios such as product
life cycles. The findings are clear. Portfolio management
and measurement techniques are significantly more sophisticated
than those of a decade ago. For more information on the conference
or this paper, please see http://www.dfma.com/forum/index.html.
Gateways to Knowledge (GTK) Mega US Government Links: If you
haven't visited the GTK for awhile, point your browser to
to see a recent addition to our link categories. We've added
a series of government- and government-related links to sources
on Department of Defense information; Public Information,
like Digital Daily and Federal World; Industry Assistance
Programs from the Department of Commerce, Small Business Association
and others; Regulatory Agencies, like EPA and FDA; Business
Services, like CIAC and NASA; as well as Labor and International
Services links. For those of us who tend to think that government
should be avoided if at all possible, these sources could
prove to be particularly useful. Have a look!
SCPD '01: The Society of Concurrent Product Development, formerly
the Society of Concurrent Engineering (SOCE) will have a biotech
track at its Fifth Annual Conference on June 6 and 7, 2001
on how Concurrent Product Development improves the drug discovery
has moved through important evolutionary steps, and concurrent
product development is now a key contributor. Towards the
end of the 1980s, pharmaceutical and biotech companies were
frustrated with the low percentage of success and poor predictability
of drug discovery based on targeting compounds that appeared
to be reasonable candidates. The industry moved to a stage-gate
process and technology-enabled high-throughput- screening
during the 1990s, in a way familiar to product developers
in other industries. Each discovery project moved from one
stage to the next in vertically (functionally) integrated
organizations. This created high costs and long delays, exclusive
of regulatory costs or delays.
Today, the biotech
industry is looking to concurrent product development as a
way to gain competitive advantage, by saving months in development
and potentially billions of dollars in expense. Four applications
appear especially promising:
- Cross functional
of genomics and proteomics technologies
of clinical data in subsequent projects.
and others related to concurrent product development for drug
discovery will be presented at SCPD '01, Concurrent Product
Development Excellence, on June 6 and 7 in Tyngsboro, Mass.
Information on the conference is available at http://www.soce.org
or contact Barbara Power at firstname.lastname@example.org
or 508 660-1793.
observations were prepared by GGI Affiliates Donald Stewart
and Hans Ludi. Don is SCPD '01 Conference Chair and was one
of the Boston Chapter's original founding members. He worked
in product marketing and new product business strategy for
over 35 years at Teradyne and for the past ten years in management
consulting. Don has a BS from MIT in Electrical Engineering
and a MBA from Harvard Business School. Hans is the current
President of the Boston SCPD Chapter. He has been the group
leader at Ciba Geigy Corporation, the Director of Critical
Care R&D at Bayer Diagnostics and is currently Chief Technology
Officer at Biodynamix, a start-up involved in proteomics for
drug discovery applications. Hans has a Ph.D. in biochemistry
from the University of Bern.]
GGI Office Moving: After approximately 15 years in Cambridge,
Massachusetts, GGI will be relocating our offices to just
west of the Boston/128 area. While timing for the move has
not yet been finalized, it will likely happen in the next
two months. We will provide everyone with further details
in future issues of RapidNews.
RapidNews is a brief e-mail publication from Goldense Group,
Inc (GGI), located in Cambridge, MA. Its subject matter includes
survey findings, company news, book reviews, key industry
conferences, and other R&D information of potential interest
to clients and associates. Jon Gilmore is responsible for
its content. Please send your communications to rn(at)goldensegroupinc.com.